Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR

…, T Ogura, M Ando, H Miyazawa, T Tanaka…

Index: Tanaka; Asami Journal of the Scientific Research Institute, Tokyo, 1954 , vol. 48, p. 287,293

Full Text: HTML

Citation Number: 2971

Abstract

Background Non–small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of